logowsbdaily | Tue, 20 Dec 2022 03:11:26 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

Immix Biopharma, Inc.
(IMMX)

Immix Biopharma, Inc.
11400 West Olympic Boulevard
Suite 200
Los Angeles, CA 90064
United States
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's d... Read More

Summary & Charts

Price$ 1.80+0.34 (+23.28%)
Day's Range$ 1.55 - 2.52 
Previous Close$ 1.46
Market Cap$ 20.89M USD
Short Interest %N/A
FloatN/A
OutstandingN/A
ExchangeNasdaqCM
IndustryBiotechnology
SectorHealthcare
Volume59.56M
Avg. Volume (20 day)3.04M
Rel. Volume (20 day)19.59
Rel. Volume (3 month)60.05
RatingB+Buy
DCFN/AStrong Buy
Debt/Equity3.86 %Neutral
ROE-134550.49 %Neutral
ROA-140200.35 %Neutral
P/E-0.46 %Strong Sell
P/B1.50 %Strong Buy
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Dec 14, 2022$ 2.02$ 2.52$ 1.55$ 1.80+0.3459,561,88019.5960.05
Dec 13, 2022$ 1.60$ 1.66$ 1.28$ 1.46-0.04161,5982.422.65
Dec 12, 2022$ 1.52$ 1.59$ 1.35$ 1.50+0.11244,2013.554.18
Dec 09, 2022$ 1.01$ 1.45$ 1.01$ 1.39+0.33200,0803.213.52
Dec 08, 2022$ 1.04$ 1.09$ 1.04$ 1.06+0.0112,0350.190.22
Dec 07, 2022$ 1.08$ 1.09$ 1.03$ 1.05-0.0315,4430.220.29
Dec 06, 2022$ 1.17$ 1.17$ 1.03$ 1.08-0.0937,4970.510.69
Dec 05, 2022$ 1.04$ 1.33$ 1.04$ 1.17+0.0219,7730.260.37
Dec 02, 2022$ 1.16$ 1.20$ 1.12$ 1.15-0.0116,9490.220.32
Dec 01, 2022$ 1.18$ 1.19$ 1.08$ 1.16-0.0524,6430.300.46
Nov 30, 2022$ 1.15$ 1.21$ 1.06$ 1.21-0.01110,4431.302.04
Nov 29, 2022$ 1.39$ 1.39$ 1.08$ 1.22-0.1449,3910.550.92
Nov 28, 2022$ 1.39$ 1.40$ 1.34$ 1.36+0.0220,1720.230.38
Nov 25, 2022$ 1.38$ 1.38$ 1.34$ 1.34-0.0315,6490.170.29
Nov 23, 2022$ 1.32$ 1.38$ 1.32$ 1.37+0.0728,7970.300.53
Nov 22, 2022$ 1.27$ 1.31$ 1.27$ 1.30-0.0217,1950.170.31
Nov 21, 2022$ 1.30$ 1.32$ 1.25$ 1.32+0.0236,5350.350.66
Nov 18, 2022$ 1.27$ 1.35$ 1.20$ 1.30+0.0831,8340.300.57
Nov 17, 2022$ 1.26$ 1.27$ 1.17$ 1.22+0.0681,8920.781.46
Nov 16, 2022$ 1.10$ 1.28$ 1.08$ 1.16+0.10129,2801.272.32

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2022-11-09BMO------------

Due Diligences

These posts should include more in-depth research by the poster about the specific company, sector or trade idea. Including any sources and citations.

thumbnail
Immix BioPharma (NASDAQ-CM: $IMMX): Biopharma market set to reach $853 Billion USD by 2030

Shining some much needed light on the BioPharma market during these turbulent times in the markets. Global biopharmaceutical sales are being spurred by several key drivers, including the growing prevalence of chronic diseases like cancer and diabetes, as well as the expanding global use of biopharma... Read More

1 comments | 14 votes
thumbnail
BioPharma historically stable during down markets: Immix BioPharma (NASDAQ-CM: $IMMX)

Shining some much needed light on the BioPharma market during these turbulent times in the markets. Global biopharmaceutical sales are being spurred by several key drivers, including the growing prevalence of chronic diseases like cancer and diabetes, as well as the expanding global use of biopharma... Read More

thumbnail
Continuous advancements in the biopharma field: Immix BioPharma (NASDAQ-CM: $IMMX)

Shining some much needed light on the BioPharma market during these turbulent times in the markets. Global biopharmaceutical sales are being spurred by several key drivers, including the growing prevalence of chronic diseases like cancer and diabetes, as well as the expanding global use of biopharma... Read More

Top Discussions

These are the top discussions over the last 24-hours that mention the IMMX stock ticker symbol.



Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.